- ACGN Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
10-K/A Filing
Aceragen (ACGN) 10-K/A2016 FY Annual report (amended)
Filed: 16 Mar 17, 12:00am
Exhibit 31.1
Certification of Chief Executive Officer pursuant to Exchange
Act Rules 13a-14 and 15d-14, as adopted pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Vincent J. Milano, certify that:
|
|
1. | I have reviewed this Amendment No. 1 to Annual Report on Form 10-K of Idera Pharmaceuticals, Inc.; and |
|
|
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
|
|
|
|
|
|
|
|
|
|
| /s/ Vincent J. Milano |
| Vincent J. Milano |
| Chief Executive Officer |
Dated: March 16, 2017
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.